{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:50:17Z","timestamp":1789167017302,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The tumor microenvironment (TME) is an essential contributor to the development and progression of malignancy. Within the TME, tumor associated macrophages (TAMs) mediate angiogenesis, metastasis, and immunosuppression, which inhibits infiltration of tumor-specific cytotoxic CD8+ T cells. In previous work, we demonstrated that the synthetic triterpenoid CDDO-methyl ester (CDDO-Me) converts breast TAMs from a tumor-promoting to a tumor-inhibiting activation state<jats:italic>in vitro<\/jats:italic>. We show now that CDDO-Me remodels the breast TME, redirecting TAM activation and T cell tumor infiltration<jats:italic>in vivo<\/jats:italic>. We demonstrate that CDDO-Me significantly attenuates IL-10 and VEGF expression but stimulates TNF production, and reduces surface expression of CD206 and CD115, markers of immunosuppressive TAMs. CDDO-Me treatment redirects the TAM transcriptional profile, inducing signaling pathways associated with immune stimulation, and inhibits TAM tumor infiltration, consistent with decreased expression of CCL2. In CDDO-Me-treated mice, both the absolute number and proportion of splenic CD4<jats:sup>+<\/jats:sup>T cells were reduced, while the proportion of CD8<jats:sup>+<\/jats:sup>T cells was significantly increased in both tumors and spleen. Moreover, mice fed CDDO-Me demonstrated significant reductions in numbers of CD4<jats:sup>+<\/jats:sup>Foxp3<jats:sup>+<\/jats:sup>regulatory T cells within tumors. These results demonstrate for the first time that CDDO-Me relieves immunosuppression in the breast TME and unleashes host adaptive anti-tumor immunity.<\/jats:p>","DOI":"10.1038\/s41598-020-63482-x","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T10:03:11Z","timestamp":1587031391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Michael S.","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretel M.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Martyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"ElTanbouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen T.","family":"Liby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Pioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"63482_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1158\/2326-6066.CIR-15-0041","volume":"3","author":"ML Broz","year":"2015","unstructured":"Broz, M. L. & Krummel, M. F. The emerging understanding of myeloid cells as partners and targets in tumor rejection. Cancer Immunol. Res. 3, 313\u2013319, https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0041 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"63482_CR2","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 379, 2108\u20132121, https:\/\/doi.org\/10.1056\/NEJMoa1809615 (2018).","journal-title":"N. Engl. J. Med."},{"key":"63482_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71\u201378, https:\/\/doi.org\/10.1038\/nrc1256 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"63482_CR4","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1126\/science.2781291","volume":"245","author":"DT Graves","year":"1989","unstructured":"Graves, D. T., Jiang, Y. L., Williamson, M. J. & Valente, A. J. Identification of monocyte chemotactic activity produced by malignant cells. Science 245, 1490\u20131493 (1989).","journal-title":"Science"},{"key":"63482_CR5","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood-2004-03-1109","volume":"104","author":"C Murdoch","year":"2004","unstructured":"Murdoch, C., Giannoudis, A. & Lewis, C. E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224\u20132234, https:\/\/doi.org\/10.1182\/blood-2004-03-1109 (2004).","journal-title":"Blood"},{"key":"63482_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1534735408319060","volume":"7","author":"C Guruvayoorappan","year":"2008","unstructured":"Guruvayoorappan, C. Tumor versus tumor-associated macrophages: how hot is the link? Integr. Cancer Ther. 7, 90\u201395, https:\/\/doi.org\/10.1177\/1534735408319060 (2008).","journal-title":"Integr. Cancer Ther."},{"key":"63482_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau, D., Gielen, P., Kroesen, M., Wesseling, P. & Adema, G. J. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138, 105\u2013115, https:\/\/doi.org\/10.1111\/imm.12036 (2013).","journal-title":"Immunology"},{"key":"63482_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361, https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010 (2014).","journal-title":"Immunity"},{"key":"63482_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/path.1027","volume":"196","author":"L Bingle","year":"2002","unstructured":"Bingle, L., Brown, N. J. & Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254\u2013265, https:\/\/doi.org\/10.1002\/path.1027 (2002).","journal-title":"J. Pathol."},{"key":"63482_CR10","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946, https:\/\/doi.org\/10.1371\/journal.pone.0050946 (2012).","journal-title":"PLoS One"},{"key":"63482_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","volume":"37","author":"BA Baldo","year":"2014","unstructured":"Baldo, B. A. Side effects of cytokines approved for therapy. Drug. Saf. 37, 921\u2013943, https:\/\/doi.org\/10.1007\/s40264-014-0226-z (2014).","journal-title":"Drug. Saf."},{"key":"63482_CR12","doi-asserted-by":"publisher","first-page":"e0149600","DOI":"10.1371\/journal.pone.0149600","volume":"11","author":"MS Ball","year":"2016","unstructured":"Ball, M. S., Shipman, E. P., Kim, H., Liby, K. T. & Pioli, P. A. CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. PLoS One 11, e0149600, https:\/\/doi.org\/10.1371\/journal.pone.0149600 (2016).","journal-title":"PLoS One"},{"key":"63482_CR13","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1124\/pr.111.004846","volume":"64","author":"KT Liby","year":"2012","unstructured":"Liby, K. T. & Sporn, M. B. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972\u20131003, https:\/\/doi.org\/10.1124\/pr.111.004846 (2012).","journal-title":"Pharmacol. Rev."},{"key":"63482_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-30","volume":"13","author":"YY Wang","year":"2014","unstructured":"Wang, Y. Y., Zhe, H. & Zhao, R. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol. Cancer 13, 30, https:\/\/doi.org\/10.1186\/1476-4598-13-30 (2014).","journal-title":"Mol. Cancer"},{"key":"63482_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/carcin\/bgv061","volume":"36","author":"C To","year":"2015","unstructured":"To, C. et al. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A\/J model of lung carcinogenesis. Carcinogenesis 36, 769\u2013781, https:\/\/doi.org\/10.1093\/carcin\/bgv061 (2015).","journal-title":"Carcinogenesis"},{"key":"63482_CR16","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","volume":"181","author":"S Matsumura","year":"2008","unstructured":"Matsumura, S. et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181, 3099\u20133107 (2008).","journal-title":"J. Immunol."},{"key":"63482_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1940-6207.CAPR-11-0404","volume":"5","author":"K Tran","year":"2012","unstructured":"Tran, K. et al. The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev. Res. 5, 726\u2013734, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-11-0404 (2012).","journal-title":"Cancer Prev. Res."},{"key":"63482_CR18","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","volume":"70","author":"K Movahedi","year":"2010","unstructured":"Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728\u20135739, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4672 (2010).","journal-title":"Cancer Res."},{"key":"63482_CR19","first-page":"865","volume":"35","author":"E Richardsen","year":"2015","unstructured":"Richardsen, E., Uglehus, R. D., Johnsen, S. H. & Busund, L. T. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer. Res. 35, 865\u2013874 (2015).","journal-title":"Anticancer. Res."},{"key":"63482_CR20","doi-asserted-by":"publisher","first-page":"e73310","DOI":"10.1371\/journal.pone.0073310","volume":"8","author":"L Fend","year":"2013","unstructured":"Fend, L. et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS One 8, e73310, https:\/\/doi.org\/10.1371\/journal.pone.0073310 (2013).","journal-title":"PLoS One"},{"key":"63482_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39\u201351, https:\/\/doi.org\/10.1016\/j.cell.2010.03.014 (2010).","journal-title":"Cell"},{"key":"63482_CR22","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.163.11.6251","volume":"163","author":"AE Loercher","year":"1999","unstructured":"Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D. & Freedman, R. S. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. 163, 6251\u20136260 (1999).","journal-title":"J. Immunol."},{"key":"63482_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/glia.20201","volume":"51","author":"JM Schartner","year":"2005","unstructured":"Schartner, J. M. et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 51, 279\u2013285, https:\/\/doi.org\/10.1002\/glia.20201 (2005).","journal-title":"Glia"},{"key":"63482_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","volume":"5","author":"N Wang","year":"2014","unstructured":"Wang, N., Liang, H. & Zen, K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front. Immunol. 5, 614, https:\/\/doi.org\/10.3389\/fimmu.2014.00614 (2014).","journal-title":"Front. Immunol."},{"key":"63482_CR25","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1111\/febs.13402","volume":"282","author":"Y Xing","year":"2015","unstructured":"Xing, Y., Zhao, S., Zhou, B. P. & Mi, J. Metabolic reprogramming of the tumour microenvironment. FEBS J. 282, 3892\u20133898, https:\/\/doi.org\/10.1111\/febs.13402 (2015).","journal-title":"FEBS J."},{"key":"63482_CR26","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921\u2013925, https:\/\/doi.org\/10.1126\/science.1252510 (2014).","journal-title":"Science"},{"key":"63482_CR27","doi-asserted-by":"publisher","first-page":"e79114","DOI":"10.1371\/journal.pone.0079114","volume":"8","author":"MJ Campbell","year":"2013","unstructured":"Campbell, M. J. et al. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One 8, e79114, https:\/\/doi.org\/10.1371\/journal.pone.0079114 (2013).","journal-title":"PLoS One"},{"key":"63482_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/path.4493","volume":"235","author":"AL Bates","year":"2015","unstructured":"Bates, A. L. et al. Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases. J. Pathol. 235, 773\u2013783, https:\/\/doi.org\/10.1002\/path.4493 (2015).","journal-title":"J. Pathol."},{"key":"63482_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0983-9","volume":"14","author":"M Miyan","year":"2016","unstructured":"Miyan, M., Schmidt-Mende, J., Kiessling, R. & Poschke, I. & de Boniface, J. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J. Transl. Med. 14, 227, https:\/\/doi.org\/10.1186\/s12967-016-0983-9 (2016).","journal-title":"J. Transl. Med."},{"key":"63482_CR30","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nri3740","volume":"14","author":"DE Speiser","year":"2014","unstructured":"Speiser, D. E. et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 14, 768\u2013774, https:\/\/doi.org\/10.1038\/nri3740 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"63482_CR31","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1084\/jem.20130762","volume":"210","author":"PD Bos","year":"2013","unstructured":"Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y. & Rudensky, A. Y. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210, 2435\u20132466, https:\/\/doi.org\/10.1084\/jem.20130762 (2013).","journal-title":"J. Exp. Med."},{"key":"63482_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1189\/jlb.1107762","volume":"84","author":"JW Pollard","year":"2008","unstructured":"Pollard, J. W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 84, 623\u2013630, https:\/\/doi.org\/10.1189\/jlb.1107762 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"63482_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623\u2013637, https:\/\/doi.org\/10.1016\/j.ccell.2014.09.006 (2014).","journal-title":"Cancer Cell"},{"key":"63482_CR34","doi-asserted-by":"crossref","unstructured":"Allavena, P. et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 28, 359\u2013369, doi:10.1002\/(SICI)1521-4141(199801)28:01&#60;359::AID-IMMU359&#62;3.0.CO;2-4 (1998).","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4"},{"key":"63482_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/039463200501800216","volume":"18","author":"T Musso","year":"2005","unstructured":"Musso, T. et al. IL-10 enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes. Int. J. Immunopathol. Pharmacol. 18, 339\u2013349 (2005).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"63482_CR36","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.20141836","volume":"212","author":"T Kitamura","year":"2015","unstructured":"Kitamura, T. et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 212, 1043\u20131059, https:\/\/doi.org\/10.1084\/jem.20141836 (2015).","journal-title":"J. Exp. Med."},{"key":"63482_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fphys.2013.00159","volume":"4","author":"JL Owen","year":"2013","unstructured":"Owen, J. L. & Mohamadzadeh, M. Macrophages and chemokines as mediators of angiogenesis. Front. Physiol. 4, 159, https:\/\/doi.org\/10.3389\/fphys.2013.00159 (2013).","journal-title":"Front. Physiol."},{"key":"63482_CR38","doi-asserted-by":"publisher","first-page":"e6695","DOI":"10.1371\/journal.pone.0006695","volume":"4","author":"M Darash-Yahana","year":"2009","unstructured":"Darash-Yahana, M. et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 4, e6695, https:\/\/doi.org\/10.1371\/journal.pone.0006695 (2009).","journal-title":"PLoS One"},{"key":"63482_CR39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728\u2013734 (2005).","journal-title":"Clin. Cancer Res."},{"key":"63482_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri2526","volume":"9","author":"M Croft","year":"2009","unstructured":"Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271\u2013285, https:\/\/doi.org\/10.1038\/nri2526 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"63482_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0008-8749(85)90017-6","volume":"92","author":"R Janicke","year":"1985","unstructured":"Janicke, R. & Droge, W. Effect of L-ornithine on proliferative and cytotoxic T-cell responses in allogeneic and syngeneic mixed leukocyte cultures. Cell Immunol. 92, 359\u2013365 (1985).","journal-title":"Cell Immunol."},{"key":"63482_CR42","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1073\/pnas.0902745106","volume":"106","author":"SZ Ben-Sasson","year":"2009","unstructured":"Ben-Sasson, S. Z. et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc. Natl Acad. Sci. USA 106, 7119\u20137124, https:\/\/doi.org\/10.1073\/pnas.0902745106 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"63482_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/sji.12212","volume":"80","author":"U Bjarnadottir","year":"2014","unstructured":"Bjarnadottir, U., Lemarquis, A. L., Halldorsdottir, S., Freysdottir, J. & Ludviksson, B. R. The suppressive function of human CD8(+) iTregs is inhibited by IL-1beta and TNFalpha. Scand. J. Immunol. 80, 313\u2013322, https:\/\/doi.org\/10.1111\/sji.12212 (2014).","journal-title":"Scand. J. Immunol."},{"key":"63482_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep24249","volume":"6","author":"S Wang","year":"2016","unstructured":"Wang, S. et al. Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity. Sci. Rep. 6, 24249, https:\/\/doi.org\/10.1038\/srep24249 (2016).","journal-title":"Sci. Rep."},{"key":"63482_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/srep11836","volume":"5","author":"M Shen","year":"2015","unstructured":"Shen, M. et al. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Sci. Rep. 5, 11836, https:\/\/doi.org\/10.1038\/srep11836 (2015).","journal-title":"Sci. Rep."},{"key":"63482_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/1940-6207.CAPR-13-0362","volume":"7","author":"J Wahler","year":"2014","unstructured":"Wahler, J. et al. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog. Cancer Prev. Res. 7, 617\u2013626, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0362 (2014).","journal-title":"Cancer Prev. Res."},{"key":"63482_CR47","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1101\/gad.1451806","volume":"20","author":"K Hotary","year":"2006","unstructured":"Hotary, K., Li, X. Y., Allen, E., Stevens, S. L. & Weiss, S. J. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes. Dev. 20, 2673\u20132686, https:\/\/doi.org\/10.1101\/gad.1451806 (2006).","journal-title":"Genes. Dev."},{"key":"63482_CR48","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1042\/BJ20030557","volume":"374","author":"MM Bernardo","year":"2003","unstructured":"Bernardo, M. M. & Fridman, R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem. J. 374, 739\u2013745, https:\/\/doi.org\/10.1042\/BJ20030557 (2003).","journal-title":"Biochem. J."},{"key":"63482_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.biomaterials.2015.07.053","volume":"68","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y., Huo, M., Xu, Z., Wang, Y. & Huang, L. Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma. Biomaterials 68, 54\u201366, https:\/\/doi.org\/10.1016\/j.biomaterials.2015.07.053 (2015).","journal-title":"Biomaterials"},{"key":"63482_CR50","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0002-9440(10)63568-7","volume":"163","author":"EY Lin","year":"2003","unstructured":"Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113\u20132126, https:\/\/doi.org\/10.1016\/S0002-9440(10)63568-7 (2003).","journal-title":"Am. J. Pathol."},{"key":"63482_CR51","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/jm0002230","volume":"43","author":"T Honda","year":"2000","unstructured":"Honda, T. et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43, 4233\u20134246 (2000).","journal-title":"J. Med. Chem."},{"key":"63482_CR52","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/jid.2014.455","volume":"135","author":"KB Long","year":"2015","unstructured":"Long, K. B. et al. The Tsk2\/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 gene. J. Invest. Dermatol. 135, 718\u2013727, https:\/\/doi.org\/10.1038\/jid.2014.455 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"63482_CR53","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1073\/pnas.091062498","volume":"98","author":"VG Tusher","year":"2001","unstructured":"Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116\u20135121, https:\/\/doi.org\/10.1073\/pnas.091062498 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"63482_CR54","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550, https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"63482_CR55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","volume":"17","author":"JK Gordon","year":"2015","unstructured":"Gordon, J. K. et al. Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res. Ther. 17, 213, https:\/\/doi.org\/10.1186\/s13075-015-0721-3 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"63482_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425, https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63482-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63482-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63482-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:38:11Z","timestamp":1696034291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63482-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63482"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63482-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"18 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Karen Liby is an inventor of patents dealing with chemical synthesis of new triterpenoids and their application in treatment of cancer, as well as in inflammatory diseases, including human kidney disease. No other author has competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6560"}}